Arabi, Leila <br/><br/>
Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.  [electronic resource] 

 -  Journal of controlled release : official journal of the Controlled Release Society  Dec 2015 
 - 275-286 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-4995 
<br/><br/><label>Standard No.: </label>10.1016/j.jconrel.2015.10.044  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Carcinoma--drug therapy<br/>Cell Line, Tumor<br/>Colonic Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Compounding<br/>Female<br/>Hyaluronan Receptors--immunology<br/>Immunoconjugates--administration & dosage<br/>Mice<br/>Mice, Inbred BALB C<br/>NIH 3T3 Cells<br/>Neoplastic Stem Cells--drug effects<br/>Polyethylene Glycols--administration & dosage<br/>Tissue Distribution<br/>Tumor Burden--drug effects